Clinical trials: COVID-19 Vaccination
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
This is a phase 1, open-label, randomized clinical trial in males and non-pregnant females, 18 years of age and older, who are in good health, have no known history of COVID-19 or SARS-CoV-2 infection, and meet all other…
- Trial name
- NCT04785144
- Testing
- mRNA-1273, mRNA-1273.351
- Where
- 4 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid-19 Vaccine, Vaccine Hesitancy
PROmotion of COvid-19 VA(X)Ccination in the Emergency Department - PROCOVAXED
The goal of this research is to increase COVID-19 vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients).
- Trial name
- PROCOVAXED (NCT05142332)
- Testing
- Covid-19 vaccine education materials
- Where
- 7 sites in United States
- Volunteers
- 541 people
- Sponsor
- University of California, San Francisco
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
COVID-19 Vaccination
RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a…
- Trial name
- MACH19 (NCT04951336)
- Testing
- FoTv
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
COVID-19 Vaccines
Improving COVID-19 Vaccine Uptake in Nursing Homes
SARS-CoV-2 vaccine, now being administered to skilled nursing facility (SNF) residents and staff, has highly variable acceptance between facilities.
- Trial name
- NCT04732819
- Testing
- High touch multi-pronged behavioral intervention
- Where
- 4 sites in United States
- Volunteers
- 23,768 people
- Sponsor
- Brown University
Vaccination Refusal, Communication
Emails Promoting COVID-19 Vaccination Among Healthcare Workers
In this evaluation, two versions of emails will be sent to Geisinger employees who have not been vaccinated against COVID-19. A delayed-contact control group will be emailed after a delay of at least two days.
- Trial name
- NCT04728594
- Testing
- Social Proof, Reframing, Scarcity Message
- Where
- United States
- Volunteers
- 9,566 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Misinformation, Vaccine Hesitancy
Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression
The COVID-19 pandemic has led to a mis/disinformation ecosystem that promotes divergent views of vaccine efficacy, as well as the legitimacy of science and medicine.
- Conditions
- Misinformation, Vaccine Hesitancy, Anxiety, Depression
- Trial name
- NCT06119854
- Testing
- Attitudinal inoculation, Cognitive-behavioral therapy-informed intervention, Conventional public health messaging
- Where
- United States
- Volunteers
- 1,419 people
- Sponsor
- City University of New York, School of Public Health
COVID-19
SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Conversational Agent Study
The long-term objective of SCALE-UP II is to increase the reach, uptake, and sustainability of COVID-19 testing among underserved populations.
- Trial name
- NCT05533359
- Testing
- Text-Messaging (TM), Conversational Agent (CA), Patient Navigation (PN)
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- University of Utah
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
Breast Cancer Related Lymphedema, Covid19
Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery.
- Trial name
- LymphVAX (NCT04872738)
- Testing
- Survey
- Where
- United States
- Volunteers
- 714 people
- Sponsor
- Massachusetts General Hospital
Covid19
SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers
SCALE-UP Utah is a community-academic partnership to address COVID-19 among Utah community health centers. The long-term objective of the project is to increase the reach, acceptance, and uptake of COVID-19 vaccines among Utah's…
- Trial name
- NCT04939519
- Testing
- Text-Messaging (TM), Patient Navigation (PN)
- Where
- United States
- Volunteers
- 65,300 people, healthy volunteers welcome
- Sponsor
- University of Utah
COVID-19
Improving COVID-19 Vaccine Uptake Among Black and Latino Youth
Black and Latino youth may be less likely to get the COVID-19 vaccine than White youth. In this study we will work with community members to come up with ways to help Black and Latino families learn more about the COVID-19…
- Trial name
- NCT05293392
- Testing
- Culturally-Tailored COVID-19 Vaccine Uptake Intervention, Standard Care
- Where
- United States
- Volunteers
- 5,792 people
- Sponsor
- Nemours Children's Health System
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
Educational Activities
Getting Asian Americans INFORMED to Facilitate COVID-19 Testing and Vaccination
This study develops and evaluates the "INdividual and Family-Oriented Responsive Messaging EDucation" (INFORMED) intervention in increasing knowledge about COVID-19 testing and decreasing decisional conflicts of getting tested…
- Trial name
- INFORMED (NCT04893265)
- Testing
- Text Messaging Only, INFORMED
- Where
- 3 sites in United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Results will be submitted, however please note that data are not yet available for all serology outcome measures. This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability…
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Trial name
- NCT04754594
- Testing
- BNT162b2
- Where
- 90 sites in United States, Brazil and 3 more
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Covid19
COVID-19 Vaccine Text Outreach
This project aims to evaluate different approaches to increase COVID-19 vaccine uptake among at-risk patients at Penn Medicine in an equitable and systematic manner through a centralized outreach program.
- Trial name
- NCT04834726
- Testing
- Opt-In (Call-Back), Opt-in (In-Bound), Standard Message
- Where
- United States
- Volunteers
- 19,554 people
- Sponsor
- University of Pennsylvania
Covid19
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and…
- Trial name
- NCT04732468
- Testing
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Coronavirus Disease 2019 (COVID-19)
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04545047
- Testing
- COVID-19 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 5,044 people
- Sponsor
- VA Office of Research and Development
COVID-19, SARS-CoV-2
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05260437
- Testing
- CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg)
- Where
- 24 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline